Narcolepsy Drugs Market to Reach Valuation of $5.36 Billion by 2026 | Top Factors That Can Win the Industry Worldwide

Narcolepsy Drugs

Rise in awareness regarding the importance of early diagnosis of narcolepsy play a major role in the growth of the narcolepsy drugs market.


The report on the global narcolepsy drugs market highlights that the market is expected to reach $2.43 billion by 2018, from $5.36 billion in 2026, growing at a CAGR of 10.3% from 2019 to 2026. The report offers the current market size and forecasts along with Porter’s Five Forces analysis to help market players, stakeholders, startups, and investors to determine the current scenario and take further steps for the future. Drivers and opportunities for highest revenue generating and fastest growing segments would help in tapping into specific segment to achieve growth. Moreover, regional analysis would assist in expansion strategies for the market players and startups.

The Covid-19 outbreak has severely affected every sector across the world. The patient numbers have been increasing every day and the majority of the countries are in complete lockdown. This has affected the supply chain and overall business operations. International trading has taken a significant downfall and has created uncertainty in the stock market. These factors have affected the narcolepsy drugs market.

To Get the Sample Copy of Report Visit @

Rise in the global prevalence of narcolepsy, presence of reimbursement policies regarding narcolepsy, and narcolepsy awareness programs and services have boosted the growth of the narcolepsy drugs market. However, adverse effects and risks related to narcolepsy drugs and delayed diagnosis or misdiagnosis hamper the market growth. On the contrary, untapped markets in developing countries are expected to create lucrative opportunities in the near future.

Daytime extreme sleepiness segment dominated the market

The daytime extreme sleepiness segment held the largest share in 2018, contributing nearly half of the market, owing to rise in prevalence of narcolepsy and other sleep disorders. However, the cataplexia segment is estimated to 10.7% during the forecast period, as patients suffering from cataplexia tend to lose muscle control and around 70% of narcolepsy patients have this symptom.

For Purchase Enquiry @

Selective serotonin reuptake inhibitor segment to manifest fastest growth

The selective serotonin reuptake inhibitor segment is estimated to portray the fastest CAGR of 11.3% during the forecast period, owing to increase in R&D activities for the development of these type of drugs by the key players. However, the sodium oxybate segment dominated the market in 2018, accounting for more than half of the market, as these drugs are highly effective to treat daytime extreme sleepiness and cataplexy.

Asia-Pacific region to portray fastest growth through 2026

The market across the Asia-Pacific region is expected to register the fastest CAGR of 11.4% during the forecast period, owing to increase in prevalence of narcolepsy and surge in adoption rate of narcolepsy drugs. However, the market across North America held the lion's share in 2018, contributing more than two-fifths of the market, owing to rise in number of narcolepsy and other sleep disorders in North America.

Access Full Report @

The Major Key Players Are:

• Ligand Pharmaceuticals
• Addrenex Pharmaceuticals
• Shire Plc
• Teva Pharmaceutical Industries Ltd.
• Arena Pharmaceuticals
• Jazz Pharmaceuticals Plc
• Bioprojet
• Novartis

Similar Reports:

Ophthalmic Drugs Market Analysis and Industry Forecast, 2027

Antimalarial Drugs Market Analysis and Industry Forecast, 2027

Dermatologicals Market Analysis and Industry Forecast, 2027

About Us:

Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Analytics LLP
+1 800-792-5285
email us here
Visit us on social media:

Source: EIN Presswire